Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
LB Pharmaceuticals Inc (LBRX) had Consolidated Net Income/Loss of $-25.20M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-25.20M |
|
-- |
|
-- |
|
$30.40M |
|
$-30.40M |
|
$5.20M |
|
$-25.20M |
|
$-25.32M |
|
$-25.20M |
|
$-25.20M |
|
|
Consolidated Net Income/Loss |
$-25.20M |
$-25.32M |
|
$-30.40M |
|
$-29.82M |
|
8.05M |
|
8.05M |
|
$-3.13 |
|
$-3.13 |
|
| Balance Sheet Financials | |
$308.43M |
|
$1.58M |
|
$4.50M |
|
$312.93M |
|
$7.44M |
|
-- |
|
$4.18M |
|
$11.62M |
|
$301.31M |
|
$301.31M |
|
$301.31M |
|
0.25M |
|
| Cash Flow Statement Financials | |
$-35.21M |
|
$-39.89M |
|
$302.56M |
|
$23.48M |
|
$250.94M |
|
$227.47M |
|
$4.19M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
41.44 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-35.26M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.37% |
|
-8.37% |
|
-8.05% |
|
-8.37% |
|
$1197.31 |
|
$-4.38 |
|
$-4.38 |
|